DEPOMED,INC. (NASDAQ:DEPO) Files An 8-K Financial Statements and Exhibits

ME Staff 8-k
-
0

DEPOMED,INC. (NASDAQ:DEPO) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Forward-Looking Statement Safe Harbor

Statements that are not historical facts contained in this Current Report on Form8-K/A, including the exhibits attached hereto, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties including, but not limited to, risks detailed in the Company’s Securities and Exchange Commission filings, including the Company’s most recent Annual Report on Form10-K and most recent Quarterly Report on Form10-Q. The inclusion of forward-looking statements should not be regarded as a representation that any of the Company’s plans or objectives will be achieved. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


DEPOMED INC Exhibit
EX-10.1 2 a17-28456_1ex10d1.htm EX-10.1 Exhibit 10.1   Execution Copy   WAIVER AND SECOND AMENDMENT TO NOTE PURCHASE AGREEMENT   THIS WAIVER AND SECOND AMENDMENT TO NOTE PURCHASE AGREEMENT,…
To view the full exhibit click here

About DEPOMED,INC. (NASDAQ:DEPO)

Depomed, Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Company’s products include NUCYNTA ER (tapentadol extended release tablets), which is a product for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate; NUCYNTA (tapentadol), which is an immediate release version of tapentadol for the management of moderate to severe acute pain in adults; Gralise, which is a once-daily product for the management of postherpetic neuralgia; CAMBIA, which is a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Zipsor, which is a NSAID for the treatment of mild to moderate acute pain, and Lazanda nasal spray, which is used for the management of break through pain in cancer patients.